News Feed

Wednesday, April 18, 2018

By Marilynn Larkin

NEW YORK (Reuters Health) - Women with breast cancer whose quality of life is negatively impacted by endocrine therapy-induced alopecia (EIA) from may benefit from minoxidil, researchers suggest.

Tuesday, April 17, 2018

By Marilynn Larkin

NEW YORK (Reuters Health) - Drugs that induce a self-inflicted cell-death process called ferroptosis could be used to target de-differentiated melanoma cells, thereby increasing the efficacy of both targeted and immune therapies, researchers suggest.

Wednesday, April 11, 2018

By David Douglas

NEW YORK (Reuters Health) - In patients with BRAF-mutant melanoma, combination treatment with encorafenib and binimetinib offers advantages over monotherapy with vemurafenib or with encorafenib, according to an open-label trial.

As many as half of melanoma patients exhibit the BRAF mutation, and both BRAF and MEK inhibitors can hinder growth of BRAF-mutated melanoma cells, researchers write in The Lancet Oncology, online March 21.

Tuesday, April 10, 2018

By Lorraine L. Janeczko

NEW YORK (Reuters Health) - In patients with active psoriatic arthritis (PsA), secukinumab improves symptoms and inhibits radiographic disease progression, researchers report.

Tuesday, April 10, 2018

By Will Boggs MD

NEW YORK (Reuters Health) - Nivolumab, alone and in combination with ipilimumab, is active against melanoma brain metastases, researchers from Australia report.

Monday, April 9, 2018

By Lisa Rapaport

(Reuters Health) - Most Americans aren't aware of cancer drug shortages, a U.S. study suggests.

In a nationally representative survey of 420 adults, just 16% said they knew about shortages of oncology drugs, researchers found.

Friday, April 6, 2018
Lesbian, gay, bisexual and transgender (LGBT) persons make up as much as 4% of the population but are barely mentioned in the basic dermatology curriculum, researchers reported in a recent study.
Thursday, April 5, 2018

By Tamara Mathias

(Reuters) - AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.

Thursday, April 5, 2018

By Will Boggs MD

NEW YORK (Reuters Health) - Screening for the HLA-A*31:01 allele is associated with a reduced incidence of carbamazepine-induced cutaneous adverse reactions in Japanese individuals, researchers report.

Wednesday, April 4, 2018

By Will Boggs MD

NEW YORK (Reuters Health) - The use of acid-suppressive medications and antibiotics in the first six months of life is associated with an increased risk of allergic diseases in early childhood, according to a retrospective study.